The estimated pooled HR for all studies suggested that the risk of death was not associated with stromal CD3+ or CD8+ TILs in ovarian cancer patients (Supplementary Figure 6; HR, 0.82; 95%CI, 0.58-1.16; PHR=0.258; I2=24.8%; fixed effects model). This evidence concerns the gene CD8A and ovarian carcinoma.